Research Paper Volume 16, Issue 15 pp 11553—11567
The deubiquitinating enzymes-related signature predicts the prognosis and immunotherapy response in breast cancer
Figure 3. Efficacy of DUBRI in predicting immunotherapy outcome. (A, B) Differences in expression levels of common immune checkpoints between high/low DUBRI groups. (C) Difference between TIDE score, Dysfunction, MSI and Exclusion between high/DUBRI and low DUBRI groups. (D) Differences in IPS scores between high/low DUBRI groups.